Alnylam Pharma, Isis Pharma Sign New Agreement In RNA Therapeutics

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) and Alnylam Pharmaceuticals, Inc. (ALNY) Friday announced forming a new agreement, which extends their partnership formed originally in 2004, to develop and commercialize RNA therapeutics.

The companies said the new deal includes a cross-license of intellectual property on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. It also comprises a non-exclusive technology IP cross-license, providing each company rights to certain of each other's technology advances for RNA therapeutics through April 2019.

The new agreement will also allow the companies to form an IP cross-license with reciprocal economic terms on four therapeutic targets, where each company obtains exclusive license rights to two therapeutic programs.